Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Published on 18 Dec 2024

Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC

in Pharmacology of Anti-Cancer Drugs

Xue Li
Shimin Chen
Yuanyuan Shi
Yuanjing Wang
Xuanzhe Wang
Qian Lin
Chao Wu
Wenshuo Fang
Peng Sun
Leina Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1464852

2,563 views

Review

Published on 18 Dec 2024

Metabolic reprogramming in lung cancer and its clinical implication

in Pharmacology of Anti-Cancer Drugs

Qingqiu Huang
Lisha Fan
Mingjing Gong
Juntong Ren
Chen Chen
Shenglong Xie

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1516650

2,723 views
4 citations

Original Research

Published on 18 Dec 2024

Development and validation of a programmed cell death index to predict the prognosis and drug sensitivity of gastric cancer

in Pharmacology of Anti-Cancer Drugs

Feizhi Lin
Xiaojiang Chen
Chengcai Liang
Ruopeng Zhang
Guoming Chen
Ziqi Zheng
Bowen Huang
Chengzhi Wei
Zhoukai Zhao
Feiyang Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1477363

1,385 views

Editorial

Published on 18 Dec 2024

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, Volume II

in Pharmacology of Anti-Cancer Drugs

Yan Zhang
Leilei Fu
Muhammad Umer Farooq Awan
Yinu Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1519858

802 views

Original Research

Published on 13 Dec 2024

β-caryophyllene sensitizes hepatocellular carcinoma cells to chemotherapeutics and inhibits cell malignancy through targeting MAPK signaling pathway

in Pharmacology of Anti-Cancer Drugs

Irum Basheer
Hai Wang
Guangyue Li
Shah Jehan
Ali Raza
Chentao Du
Najeeb Ullah
Dangdang Li
Guangchao Sui

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1492670

2,127 views
2 citations

Correction

Published on 13 Dec 2024

Corrigendum: Role of β-interferon inducer (DEAE-Dextran) in tumorigenesis by VEGF and NOTCH1 inhibition along with apoptosis induction

in Pharmacology of Anti-Cancer Drugs

Anita K. Bakrania
Bhavesh C. Variya
Snehal S. Patel

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1433625

671 views

Mini Review

Published on 11 Dec 2024

Cellular components of tumor microenvironment: understanding their role in lymphatic metastasis of tumors

in Pharmacology of Anti-Cancer Drugs

Ziyi Wang
Zehui Li
Xiangyu Sun
Wanfu Men
Yan Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1463538

1,655 views

Review

Published on 11 Dec 2024

NGF-mediated crosstalk: unraveling the influence of metabolic deregulation on the interplay between neural and pancreatic cancer cells and its impact on patient outcomes

in Pharmacology of Anti-Cancer Drugs

Francesca Trentini
Virginia Agnetti
Martina Manini
Elisa Giovannetti
Ingrid Garajová

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1499414

1,725 views

Original Research

Published on 11 Dec 2024

Ailanthone blocks mitophagy to promote mtDNA leakage through BAX-BAK1 pores and suppress hepatocellular carcinoma cell proliferation

in Pharmacology of Anti-Cancer Drugs

Yan Qin
Ying Gao
Dan Wu
Qing-Qing Liu
Chang Su
Guan Liu
Le Yang
Ming-Gao Zhao
Jing-Yue Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1509482

2,080 views
1 citation

Case Report

Published on 10 Dec 2024

Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective

in Pharmacology of Anti-Cancer Drugs

Xiaoli Mu
Yan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1413897

1,422 views

Original Research

Published on 10 Dec 2024

HDC downregulation induced by chronic stress promotes ovarian cancer progression via the IL-6/STAT3/S100A9 pathway

in Pharmacology of Anti-Cancer Drugs

Zhicong Chen
Jinming Cao
Zhijun Xiao
Zhen Yang
Yuanchi Cheng
Jingjing Duan
Ting Zhou
Feng Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1485885

2,377 views
1 citation

Editorial

Published on 09 Dec 2024

Editorial: Genomic discoveries and pharmaceutical development in urologic tumors

in Pharmacology of Anti-Cancer Drugs

Jialin Meng
Huan Yang
Lei Yin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1508979

903 views

Original Research

Published on 06 Dec 2024

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

in Pharmacology of Anti-Cancer Drugs

Yuanbin Huang
Meiqi Xu
Xinmiao Ma
Wei Wang
Chen Shen
Fei Liu
Zhiqi Chen
Jiawen Wang
Qian Guo
Xiancheng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1503154

2,166 views
2 citations

Systematic Review

Published on 06 Dec 2024

Efficacy and safety of TACE combined with traditional Chinese medicine versus TACE alone in hepatocellular carcinoma: bayesian network meta-analysis and pharmacological mechanisms study

in Pharmacology of Anti-Cancer Drugs

Li Chen
Xiu-Ling Zhu
Jie Lin
Dong-Liang Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1495343

2,357 views
1 citation

Systematic Review

Published on 05 Dec 2024

Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses

in Pharmacology of Anti-Cancer Drugs

Yunfang Wang
Jianguo Xu
Yafei Xie
Dan Zhou
Mingyue Guo
Yu Qin
Kang Yi
Jinhui Tian
Tao You

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1479983

2,724 views
2 citations

Case Report

Published on 04 Dec 2024

Pemigatinib combined with immunotherapy and stereotactic body radiation therapy for FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis: a Case Report

in Pharmacology of Anti-Cancer Drugs

Jiamin Guo
Lingqi Sun
Ye Chen
Ji Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1509891

1,881 views
2 citations